Reports of Practical Oncology and Radiotherapy最新文献

{"title":"Clinical stage-dependent expression of MRE11 and its association with laryngeal cancer progression.","authors":"Zdenka Pechacova, Radka Lohynska, Zuzana Spurkova, Vratislav Sedivec, Marian Svajdler, Tereza Drbohlavova, Petra Tesarova, Miloslav Pala","doi":"10.5603/rpor.112754","DOIUrl":"10.5603/rpor.112754","url":null,"abstract":"<p><strong>Background: </strong>Radiotherapy is a mainstay of treatment for laryngeal cancer. MRE11, a core component of the MRN complex, contributes to radioresistance and also has a signalling function. This study examines the association between MRE11 expression and tumour progression in patients with laryngeal cancer treated at Bulovka University Hospital in Prague.</p><p><strong>Materials and methods: </strong>This retrospective study included 108 patients with laryngeal cancer treated with radiotherapy. Immunohistochemical analysis was performed on pretreatment biopsy samples to evaluate the expression of selected DNA repair proteins and statistically assess their impact on treatment outcomes.</p><p><strong>Results: </strong>Of the proteins studied, MRE11 showed the strongest statistical association, with significantly higher expression in early clinical stages I-II and lower expression in stages III-IV (p < 0.001). Higher MRE11 expression was associated with better overall survival (p < 0.001) and longer progression-free survival (p = 0.025). No significant relationship was observed between analysed protein expression and treatment toxicity.</p><p><strong>Conclusions: </strong>In our cohort of patients with laryngeal carcinoma treated with radiotherapy, elevated immunohistochemical expression of MRE11 was associated with less advanced disease and improved treatment outcomes, in contrast to findings in other head and neck cancers. This discrepancy may reflect the context-dependent function of MRE11. Further research is needed to clarify the prognostic role of MRE11 and its potential use in guiding personalised treatment.</p>","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"31 4","pages":"492-500"},"PeriodicalIF":1.7,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13544048/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148897960","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"API-enabled integration of Pylinac with QATrack+ for automated EPID-based QA on Elekta linear accelerators: a technical note.","authors":"Oussama El Mouden, Hamza Sekkat, Ahmed Bannan, Redouane El Baydaoui, Mustapha Bougteb, Mounir Mkimel, Abdellah Khallouqi, Maroine Tahiri, Omar El Rhazouani, Yasmina Berrada","doi":"10.5603/rpor.112213","DOIUrl":"10.5603/rpor.112213","url":null,"abstract":"<p><strong>Background: </strong>EPID quality assurance (QA) workflows remain largely manual and are difficult to standardise across treatment machines. This limits efficiency, increases operator dependency, and complicates consistent reporting and data sharing between systems.</p><p><strong>Materials and methods: </strong>We integrated Pylinac image analysis into QATrack+ and adopted an API-oriented publication model to enable structured data export and interoperability.</p><p><strong>Results: </strong>EPID images from an Elekta Versa HD (6-18 MV) were analysed for field size, flatness, symmetry, and MLC Picket Fence metrics, showing close agreement with reference measurements.</p><p><strong>Conclusions: </strong>This workflow supports standardised, automated, and interoperable EPID QA reporting.</p>","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"31 4","pages":"549-553"},"PeriodicalIF":1.7,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13544044/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148898025","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A systematic review: management of radiation-induced moist desquamation.","authors":"Sneha Raja, Sujatha Kuppusamy, Christian Gnanaraj Johnson, Jayasutha Jayram, Satish Srinivas Kondaveeti","doi":"10.5603/rpor.111765","DOIUrl":"10.5603/rpor.111765","url":null,"abstract":"<p><strong>Background: </strong>Radiotherapy is a cornerstone in cancer treatment, but is frequently correlated with acute cutaneous toxicity, particularly in patients with head, neck, and breast cancers. This systematic review evaluates the efficacy of interventions for managing grade III moist desquamation among various cancer patients receiving radiotherapy.</p><p><strong>Materials and methods: </strong>A total of 676 studies were screened, and 10 randomised controlled trials were analysed based on inclusion criteria.</p><p><strong>Results: </strong>Interventions such as Mepitel Film, boron-based gel, and 0.1% Mometasone Furoate demonstrated significant efficacy in reducing the incidence and severity of moist desquamation compared to standard creams or placebo. Hydroactive colloid gels and aloe vera showed promise in alleviating symptoms and improving treatment adherence. Betamethasone effectively reduced grade 2 dermatitis but limitedly impacted severe grade 3 reactions.</p><p><strong>Conclusions: </strong>The findings highlight the importance of tailoring interventions to individual patient needs and emphasize the need for further studies to validate treatments, explore long-term outcomes, and improve patient quality of life during radiotherapy.</p>","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"31 4","pages":"582-590"},"PeriodicalIF":1.7,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13544027/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148897996","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sentinel lymph node distribution in endometrial cancer: clinical patterns and implications from a 292-patient cohort.","authors":"Wiktor Szatkowski, Karolina W Pniewska, Małgorzata U Nowak-Jastrząb, Kamil Kisielewicz, Janusz Ryś, Tomasz Banaś, Jerzy Jakubowicz, Paweł Blecharz","doi":"10.5603/rpor.111981","DOIUrl":"10.5603/rpor.111981","url":null,"abstract":"<p><strong>Background: </strong>Sentinel lymph node biopsy (SLNB) is an established alternative to systematic lymphadenectomy in endometrial cancer (EC). However, the anatomical variability of sentinel lymph node (SLN) locations remains incompletely characterised. This study assessed SLN distribution in a single-centre cohort and compared findings with published data.</p><p><strong>Materials and methods: </strong>We retrospectively analysed 292 patients with EC treated at the Maria Sklodowska-Curie National Research Institute of Oncology, Krakow Branch (2016-2025). All underwent SLN mapping using technetium-99m (Tc-99m), indocyanine green (ICG), Patent Blue, or their combinations. Bilateral detection failures were managed according to an established intraoperative algorithm. SLNs were classified anatomically, and outcomes were compared across mapping techniques. Histopathological assessment included ultrastaging.</p><p><strong>Results: </strong>A total of 526 SLNs were identified (mean 1.8 per patient). The most common locations were the obturator (48.7%) and internal iliac (25.1%) regions. Bilateral detection was achieved in 87.0% of patients, unilateral in 12.0%, and no detection in 1.0%. Metastases were found in 41 SLNs (7.8%) from 34 patients (11.6%), most frequently in obturator (41.5%) and internal iliac (14.6%) nodes. The use of tracer combinations (ICG + Tc-99m or Tc-99m + Patent Blue) improved detection when preoperative Tc-99m mapping was incomplete. Para-aortic SLNs were rare (1.5%) but carried a significantly higher risk of metastasis.</p><p><strong>Conclusions: </strong>Sentinel lymph node biopsy is an effective and safe method for nodal assessment in EC, with the obturator and internal iliac regions being the most frequent SLN sites. Variability in SLN locations appears to depend on mapping technique, tracer type, and surgical access. Standardization of procedures and prospective comparative studies are essential to further optimise SLNB in gynaecological oncology.</p>","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"31 4","pages":"501-509"},"PeriodicalIF":1.7,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13544032/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148898003","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of augmented reality for interstitial brachytherapy optimisation: a prospective phantom-based study protocol and preliminary results.","authors":"Artur J Chyrek, Adam Kluska, Grzegorz Bielęda","doi":"10.5603/rpor.112212","DOIUrl":"10.5603/rpor.112212","url":null,"abstract":"<p><strong>Background: </strong>Interstitial brachytherapy enables highly conformal tumor irradiation while limiting exposure of surrounding tissues, but its successful execution requires advanced spatial orientation and manual precision. Augmented reality (AR) may support these procedures by providing three-dimensional visualisation of treatment planning data within the procedural environment. This study presents a prospective, phantom-based protocol with preliminary results evaluating the impact of AR guidance on implantation accuracy and procedure duration in interstitial brachytherapy.</p><p><strong>Materials and methods: </strong>A total of 136 implantation procedures are planned using 34 custom-made, tissue-equivalent phantoms. Each phantom undergoes CT imaging and treatment planning with the Oncentra Brachy system. Implantations are performed using a conventional freehand technique and an AR-assisted approach. The AR system, based on Microsoft HoloLens 2 and the HOLO BR platform, enables visualisation of DICOM RT data, including three-dimensional anatomical structures and applicator trajectories. Primary endpoints are implantation accuracy, defined as spatial deviation from the planned needle position, and total procedure time. This manuscript additionally reports preliminary results from a pilot phase comprising 12 AR-assisted and 12 conventional procedures, analysed using non-parametric statistical tests.</p><p><strong>Results: </strong>All pilot procedures were completed successfully. Implantation accuracy was numerically improved with AR guidance compared to the conventional technique, while procedure time was longer in the AR-assisted arm; however, neither difference reached statistical significance.</p><p><strong>Conclusions: </strong>This study provides an experimental framework and initial quantitative data on AR-guided interstitial brachytherapy under controlled conditions. The preliminary results support the feasibility of AR-assisted implantation and justify completion of the full experimental protocol and subsequent clinical validation.</p>","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"31 4","pages":"569-575"},"PeriodicalIF":1.7,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13544056/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148898007","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Integrated pathology and interventional diagnostic approach to a metastatic grade 1 pancreatic neuroendocrine tumour: a clinical vignette of delayed diagnosis in a low-resource setting.","authors":"Oluwaseun Theophilus Babalola, Stephanie Yemisi Damitan","doi":"10.5603/rpor.111327","DOIUrl":"10.5603/rpor.111327","url":null,"abstract":"","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"31 4","pages":"602-604"},"PeriodicalIF":1.7,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13544045/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148898038","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hypofractionated chemoradiotherapy for non-small-cell lung cancer in a real-world setting: a single-centre experience.","authors":"Irene Fajardo-Paneque, Sarah Sayago-Gil, Raquel Rodríguez-Sánchez, Amanda Ruiz-Herrero, Magdalena Del Río-Balbuena, Javier Jaén-Olasolo","doi":"10.5603/rpor.112682","DOIUrl":"10.5603/rpor.112682","url":null,"abstract":"<p><strong>Background: </strong>This study aimed to evaluate tolerability and outcomes of hypofractionated radiotherapy for non-small cell lung cancer (NSCLC), with or without concomitant or prior chemotherapy, in a real-world single-centre setting.</p><p><strong>Materials and methods: </strong>Between August 2017 and September 2024, 117 consecutive NSCLC patients treated with hypofractionated radiotherapy were prospectively registered. The predominant regimen was 55 Gy in 20 fractions (94.1%), delivered either concurrently or after chemotherapy.</p><p><strong>Results: </strong>A total of 102 patients were analysed: 6 had stage II, 82 had stage III, and 14 had stage IV disease. Fifty-nine patients received concurrent chemoradiotherapy (conc-RChT) and 43 sequential chemotherapy followed by radiotherapy (seq-RChT). Median disease-free and overall survival were 18.3 and 22.0 months, respectively. Eastern Cooperative Oncology Group (ECOG) performance status was the only independent prognostic factor for overall survival (30.3 months for ECOG 0 <i>vs.</i> 18.9 months for ECOG 1-2; p = 0.012). Acute esophagitis occurred in 34% (grade 1), 16.7% (grade 2), and 3.9% (grade 3). Acute pneumonitis was reported in 12.7% (grade 1) and 8.8% (grade 2); late grade 1 pneumonitis in 4.9%.</p><p><strong>Conclusions: </strong>To our knowledge, this is the first large real-world series from our country including unselected NSCLC patients treated with hypofractionated radiotherapy. Although 55 Gy in 20 fractions is standard in the UK, its use remains limited locally, particularly with conc-RChT. Our findings support hypofractionation as an effective and well-tolerated option, especially in high-volume centres.</p>","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"31 4","pages":"510-519"},"PeriodicalIF":1.7,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13544055/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148898009","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Estimation of the α/β ratio for metastatic melanomas in a patient based on actual responses to radiation therapy delivered with various fractionation schedules.","authors":"Yuto Imai, Yuta Shibamoto, Seiya Takano, Minori Niwa","doi":"10.5603/rpor.111324","DOIUrl":"10.5603/rpor.111324","url":null,"abstract":"<p><strong>Background: </strong>Radiation response of 41 metastatic melanomas treated with various fractionation schedules in a single patient was analyzed to identify an α/β ratio that fits the clinical data.</p><p><strong>Materials and methods: </strong>Of the 41 tumors, 37 were located within 5 cm from the body surface, while 4 were deep-seated. The patient received radiation doses between 32 and 52.5 Gy in 4-18 fractions over 7 series of radiotherapy during 5 months. Since no tumors developed recurrence between 4 and 7 months after radiation, local status at 4 months was used as an endpoint. Local control was analyzed in relation to gross tumor volume (GTV) and biological effective dose (BED)_{2 Gy, 6 Gy, 10 Gy, 15 Gy, 20 Gy, and 25 Gy} to identify a boundary threshold to classify controlled from uncontrolled tumors.</p><p><strong>Results: </strong>All tumors exhibited partial or complete responses; however, 11 developed local recurrence. In figures plotting GTV <i>vs.</i> BED for all 41 tumors, upward-sloping lines to discriminate controlled from uncontrolled tumors could be drawn for all BEDs between 2 and 25 Gy, but 34-68% of the tumors failed to meet the threshold. When non-deep-seated and deep-seated tumors were analyzed separately, upward-sloping lines could be drawn using α/β ratios of 10 and 15 Gy; no tumors recurred above the lines whereas some of the tumors recurred below the lines. In contrast, it was impossible to draw such lines using lower or higher α/β ratios.</p><p><strong>Conclusions: </strong>An α/β ratio of 10-15 Gy appeared to more accurately reflect the actual radiation response of metastatic melanomas in this patient.</p>","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"31 3","pages":"358-366"},"PeriodicalIF":1.7,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13364272/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148438348","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multi-modality brain tumor segmentation using dual-attention generative adversarial network.","authors":"Daisuke Kawahara, Takahiro Nishimura, Masato Tsuneda, Hiroyuki Okamoto, Mitsuhiro Nakamura, Teiji Nishio, Yuji Murakami","doi":"10.5603/rpor.110813","DOIUrl":"10.5603/rpor.110813","url":null,"abstract":"<p><strong>Background: </strong>Brain malignant tumor needs accurate and fast segmentation for clinical diagnostics and radiation treatment planning. However, multi-contrast magnetic resonance images (MRI) are used to segment the necrotic, enhancing, and non-enhancing tumor (non-ET) regions. The current study improved an auto-segmentation model using a generative adversarial network (GAN) incorporated dual-attention (DAtGAN) on MRI images of glioma.</p><p><strong>Materials and methods: </strong>A dataset used was that from the brain tumor segmentation (BraTS) challenge 2017 on Medical Image Computing and Computer Assisted Intervention Society (MICCAI). The DAtGAN introduced an attention module that helps to exploit the global information effectively for both the generator and discriminator of the GAN. The segmentation performance of the DAtGAN was compared with the conventional GAN.</p><p><strong>Results: </strong>The average Dice similarity coefficient (DSC) of the GAN model was 0.85 for the ET, 0.89 for the core tumor region (CT), and 0.87 for the whole tumor (WT) region. The average DSC of the DAtGAN model was 0.88 for the ET, 0.92 for the CT, and 0.91 for the WT. The Intersection Over the Union was higher and the maximum Hausdorff distance (HD) was smaller for the DAtGAN than for the GAN model.</p><p><strong>Conclusions: </strong>The current study evaluated the auto-segmentation of glioma patients using the DAtGAN model. The proposed DAtGAN model is potentially valuable for improving the segmentation performance compared with other deep learning and atlas-based segmentation models. These results suggest that DAtGAN could be a valuable tool in clinical settings, providing more accurate and efficient segmentation for glioma patients, and ultimately enhancing treatment planning and outcomes.</p>","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"31 3","pages":"311-321"},"PeriodicalIF":1.7,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13364226/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148438424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cancer risk associated with CT imaging: quantifying the evidence, addressing misconceptions, and optimizing risk communication.","authors":"Amy Avakian, Krystin Avakian, Ryan Patel","doi":"10.5603/rpor.111333","DOIUrl":"10.5603/rpor.111333","url":null,"abstract":"<p><p>Computed tomography (CT) is a cornerstone of modern diagnostics, but its increasing use has raised concerns about long-term cancer risks associated with ionizing radiation exposure. This narrative review evaluates the magnitude of cancer risk linked to CT imaging, identifies vulnerable populations, clarifies common misconceptions about radiation dose, and explores emerging strategies for risk reduction and patient-centered communication. Evidence from epidemiologic cohort studies, radiobiological models, technological assessments, and public health guidelines published over the past two decades is synthesized. The cancer risk associated with CT is small but quantifiable, particularly in pediatric and high-utilization populations. Recent advancements in CT technology have enabled substantial dose reductions, including photon-counting detector systems and AI-driven dose optimization tools that improve diagnostic quality while lowering exposure. Contemporary meta-analyses (2018-2024) also provide clearer dose-response estimates for low-dose medical radiation. Advances in imaging technology and protocol optimization have significantly reduced per-scan radiation doses; however, physician awareness and patient education remain inconsistent. Looking forward, precision imaging strategies, cumulative radiation tracking, and ultra-low-dose CT platforms represent promising future directions for minimizing risk. Minimizing harm while preserving diagnostic benefit requires evidence-based utilization, personalized imaging protocols, and transparent communication of risk, especially among high-risk groups.</p>","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"31 3","pages":"450-460"},"PeriodicalIF":1.7,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13364223/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148438381","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}